{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=16", "query": { "intervention": "Dose level 3", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 17825, "total_pages": 1783, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T09:10:36.808Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06633419", "title": "A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Opevesostat", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Fludrocortisone acetate", "type": "DRUG" }, { "name": "Carbamazepine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 14, "start_date": "2024-12-18", "completion_date": "2025-05-13", "has_results": false, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-11-13T09:10:36.808Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06633419" }, { "nct_id": "NCT01675128", "title": "ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Neoplasms", "Colorectal Carcinoma", "Colorectal Tumors" ], "interventions": [ { "name": "ISIS 183750", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2012-08", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2016-04-25", "last_synced_at": "2026-11-13T09:10:36.808Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01675128" }, { "nct_id": "NCT00689065", "title": "Safety Study of CALAA-01 to Treat Solid Tumor Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Solid Tumor" ], "interventions": [ { "name": "CALAA-01", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calando Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2008-05", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2013-11-01", "last_synced_at": "2026-11-13T09:10:36.808Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California • San Antonio, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00689065" }, { "nct_id": "NCT00429364", "title": "Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Marfan Syndrome" ], "interventions": [ { "name": "Losartan Potassium", "type": "DRUG" }, { "name": "Atenolol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carelon Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "25 Years", "sex": "ALL", "summary": "6 Months to 25 Years" }, "enrollment_count": 608, "start_date": "2007-01", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-11-13T09:10:36.808Z", "location_count": 24, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00429364" }, { "nct_id": "NCT02131064", "title": "A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2014-06-25", "completion_date": "2018-05-29", "has_results": true, "last_update_posted_date": "2019-07-02", "last_synced_at": "2026-11-13T09:10:36.808Z", "location_count": 16, "location_summary": "Fullerton, California • Los Angeles, California • San Luis Obispo, California + 13 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Luis Obispo", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02131064" }, { "nct_id": "NCT01366144", "title": "Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Carcinoma", "Carcinoma of Unknown Primary", "Endometrial Carcinoma", "Esophageal Carcinoma", "Liver Failure", "Lung Carcinoma", "Malignant Head and Neck Neoplasm", "Malignant Testicular Neoplasm", "Melanoma", "Metastatic Malignant Solid Neoplasm", "Ovarian Carcinoma", "Renal Failure", "Unresectable Malignant Neoplasm", "Urothelial Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2011-06-20", "completion_date": "2027-03-03", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-13T09:10:36.808Z", "location_count": 17, "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01366144" }, { "nct_id": "NCT06598332", "title": "5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Graft-Versus-Host Disease(GVHD)" ], "interventions": [ { "name": "5-Azacytidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 0, "start_date": "2025-08", "completion_date": "2029-05-01", "has_results": false, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-11-13T09:10:36.808Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06598332" }, { "nct_id": "NCT04321031", "title": "Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nonalcoholic Fatty Liver Disease", "Nonalcoholic Steatohepatitis With Liver Fibrosis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "PF-06865571", "type": "DRUG" }, { "name": "PF-05221304", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 256, "start_date": "2020-06-15", "completion_date": "2024-02-21", "has_results": true, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-11-13T09:10:36.808Z", "location_count": 184, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 101 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04321031" }, { "nct_id": "NCT00141037", "title": "Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kidney Diseases", "Kidney Transplantation", "Kidney Transplant", "Renal Transplantation", "Renal Transplant" ], "interventions": [ { "name": "Daclizumab", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Ganciclovir", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Trimethoprim and sulfamethoxazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 130, "start_date": "2004-03", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-11-13T09:10:36.808Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00141037" }, { "nct_id": "NCT05308472", "title": "Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Erythropoietic Protoporphyria" ], "interventions": [ { "name": "DISC-1459", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Disc Medicine, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2022-10-31", "completion_date": "2024-08-23", "has_results": true, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-11-13T09:10:36.808Z", "location_count": 9, "location_summary": "Birmingham, Alabama • San Francisco, California • Miami, Florida + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05308472" } ] }